Delta阿片受体、β-arrestin1、Bcl-2在溃疡性结肠炎大鼠脾脏组织中的表达及乌梅丸的干预作用  

Wumeiwan treatment alters the expression of delta-opioid receptor, β-arrestin 1 and Bcl-2 in the spleen tissue of rats with ulcerative colitis

作　　者：柯琴梅[1] 吴霁[2] 范恒[3] 

机构地区：[1]华中科技大学同济医学院附属协和医院老年病科,湖北省武汉市430022 [2]南昌大学第三附属医院,江西省南昌市330000 [3]华中科技大学同济医学院附属协和医院中西医结合科,湖北省武汉市430022

出　　处：《世界华人消化杂志》2013年第13期1164-1170,共7页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.81072944;湖北省自然科学基金资助项目;No.2011CDB386~~

摘　　要：目的:观察溃疡性结肠炎(ulcerative colitis,UC)大鼠脾脏组织Delta阿片受体、β-arrestin1、Bcl-2 mRNA和蛋白表达及乌梅丸的干预作用,旨在研究乌梅丸治疗结肠炎的机制.方法:56只SD大鼠随机分成空白对照组、结肠炎模型组、美沙拉嗪组、乌梅丸组(每组14只).除空白对照组外,其他3组均应用2,4,6-三硝基苯磺酸灌肠.模型建成2 d后,空白对照组和结肠炎模型组分别以蒸馏水3 mL/只灌胃,美莎拉嗪组用美莎拉嗪混悬液(浓度50 g/L)、乌梅丸组用乌梅丸液(浓度0.51 g/L)以3 mL/只灌胃,连续给药15 d后取脾脏组织,应用Realtime-PCR检测Delta阿片受体、β-arrestin1、Bcl-2 mRNA的表达,应用Western blot技术检测Delta阿片受体、β-arrestin1、Bcl-2蛋白的表达.结果:空白对照组Delta阿片受体、β-arrestin1及Bcl-2 mRNA的相对表达分别为1.11±0.10、1.05±0.06及1.06±0.04;蛋白的相对表达分别为0.48±0.08、0.62±0.07及0.76±0.10.结肠炎模型组Delta阿片受体、β-arrestin1及Bcl-2的mRNA的相对表达分别为2.50±0.25、3.27±0.41及2.48±0.43;蛋白的相对表达分别为1.04±0.17、1.50±0.15及1.26±0.20.美沙拉嗪组Delta阿片受体、β-arrestin1及Bcl-2 mRNA的相对表达分别为1.52±0.09、1.63±0.27及1.56±0.09;蛋白的相对表达分别为0.68±0.17、0.77±0.15及0.96±0.16.乌梅丸组Delta阿片受体、β-arrestin1及Bcl-2 mRNA的相对表达分别为1.54±0.13、1.54±0.14及1.57±0.15;蛋白的相对表达分别为0.68±0.14、0.74±0.19及0.93±0.11.与空白对照组相比,结肠炎模型组Delta阿片受体、β-arrestin1、Bcl-2 mRNA和蛋白表达显著升高(P<0.05);与结肠炎模型组相比,乌梅丸组、美沙拉嗪组Delta阿片受体、β-arrestin1、Bcl-2 mRNA和蛋白表达显著下降(P<0.05),且乌梅丸组和美沙拉嗪组Delta阿片受体、β-arrestin1、Bcl-2 mRNA和蛋白表达均无显著差异(P>0.05).结论:乌梅丸下调UC大鼠脾脏组织Delta阿片受体、β-arrestin1、Bcl-2 mRNA和蛋白表达发�AIM：To investigate the effect of Wumeiwan treatment on the expression of delta-opioid receptor,β-arrestin 1 and Bcl-2 in the spleen tissue of rats with ulcerative colitis.METHODS：Fifty-six SD rats were randomly devided into a control group,a colitis model group,a mesalazine group and a Wumeiwan group（14 rats in each group）.Ulcerative colitis was induced in rats with 2,4,6-trinitrobenzenesulfonic acid.Two days after induction of ulcerative colitis,the control group and colitis model group were administered intragastrically with normal saline,while the mesalazine group and Wumeiwan group were intragastrically given mesalazine（50 g/L） and Wumeiwan（0.51 g/ L）,respectively.All rats were treated for 15 d.Spleen tissue samples were taken to detect the mRNA and protein expression of delta-opioid receptor,β-arrestin 1 and Bcl-2 by quantitative RT-PCR and Western blot.RESULTS：The relative expression levels of delta-opioid receptor,β-arrestin 1 and Bcl-2 mRNAs and proteins were significantly higher in the colitis model group than in the control group（mRNA：2.50±0.25 vs 1.11±0.10,3.27±0.41 vs 1.05±0.06,2.48±0.43 vs 1.06±0.04;all P0.05;protein：1.04±0.17 vs 0.48±0.08,1.50±0.15 vs 0.62±0.07,1.26±0.20 vs 0.76±0.10;all P0.05）.Treatment with Wumeiwan（mRNAs：1.54±0.13,1.54±0.14,1.57±0.15;proteins：0.68±0.14,0.74±0.19 and 0.93± 0.11） and mesalazine（mRNAs：1.52±0.09,1.63±0.27 and 1.56±0.09;proteins：0.68±0.17,0.77±0.15 and 0.96±0.16） significantly decreased the expression of deltaopioid receptor,β-arrestin1 and Bcl-2 mRNAs and proteins compared to the colitis model group（all P0.05）.There was no significant difference in the expression of these mRNAs and proteins between the Wumeiwan group and the mesalazine group（all P 0.05）.CONCLUSION：Wumeiwan treatment attenuates ulcerative colitis possibly by significantly decreasing the mRNA and protein expression of delta-opioid receptor,β-arrestin 1 and Bcl-2 in the spleen tissue of rats with ulcerative colitis.

关 键 词：乌梅丸 TNBS诱导的结肠炎 Delta阿片受体 -arrestin1 BCL-2 

分 类 号：R574.62[医药卫生—消化系统]